Summary of nih hcl specific trials robert j kreitman m d rk21n nih 301 648 7375
This presentation is the property of its rightful owner.
Sponsored Links
1 / 4

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375 PowerPoint PPT Presentation


  • 42 Views
  • Uploaded on
  • Presentation posted in: General

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375 Elizabeth Maestri, RN, [email protected] , 301-402-5633 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter)

Download Presentation

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Summary of nih hcl specific trials robert j kreitman m d rk21n nih 301 648 7375

  • Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected], 301-648-7375

  • Elizabeth Maestri, RN, [email protected], 301-402-5633

  • Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter)

    • Multiply relapsed (prior purine analogs or purine analog + rituximab)

    • Recombinant immunotoxin, non-chemotherapy

    • No prior recombinant immunotoxin allowed

  • BRAF & MEK Inhibitors Dabrafenib & Trametinib for Hairy Cell Leukemia (multicenter)

    • Multiply relapsed (prior purine analogs or purine analog + rituximab)

    • Oral agents, taken daily

    • Must have BRAF V600E+ HCL

  • Randomized Phase II Trial of Rituximab With Pentostatin or Bendamustine for Multiply Relapsed HCL

    • Multiply relapsed

    • Pentostatin or bendamustine chemotherapy and rituximab monoclonal antibody

    • HCL or HCLv, prior recombinant immunotoxin or splenectomy allowed.

  • LMB-2 to Treat Hairy Cell Leukemia (NIH)

    • Multiply relapsed

    • Prior recombinant immunotoxin allowed

    • Recombinant immunotoxin, non-chemotherapy

  • Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia (NIH)

    • Early HCL: Newly diagnosed or once relapsed

    • Cladribine chemotherapy and rituximab monoclonal antibody

  • Multicenter study of BTK inhibitor Ibrutinib for relapsed HCL

    • Relapsed HCL or HCLv

    • Oral agent, taken daily


  • Login